MENINGIOMA research

The col­lec­tive projects aim to pro­vide a com­pre­hen­sive inves­ti­ga­tion of the bio­log­i­cal back­ground of clin­i­cal­ly aggres­sive menin­giomas. Lever­ag­ing a ret­ro­spec­tive cohort of 251 cas­es and gen­er­at­ing a prospec­tive cohort of 145 cas­es, the con­sor­tium plans to iden­ti­fy reli­able mark­ers for diag­nos­tics, prog­no­sis, and treat­ment deci­sions as well as mod­el nov­el tar­gets for non­re­sectable and clin­i­cal­ly aggres­sive menin­giomas. This research will direct­ly influ­ence and con­sid­er­ably improve patient care.

Identification

Sub­pro­jects 1, 3, 4, 7, & 5 focus on the inte­gra­tion of genet­ic sub­groups, extent of tumor resec­tions, and intra­op­er­a­tive assessment.
  • SP 1 & 3 – Iden­ti­fi­ca­tion of nov­el tis­sue bio­mark­ers and nov­el bio­log­i­cal subgroups
  • SP 4 & 7 – Iden­ti­fi­ca­tion of liq­uid biop­sy devel­op­ment and PET pro­file of aggres­sive growth
  • SP 5 – Iden­ti­fi­ca­tion of clear delin­eation of tumor bor­der, infil­tra­tion, and intra-OP spa­tial subtyping

Model

Sub­pro­ject 6 focus­es on employ­ing and eval­u­at­ing the mark­ers of oth­er sub­pro­jects and using in-vit­ro and in-vivo mod­el gen­er­a­tion to test for iden­ti­fi­ca­tion parameters.

Treatment

Sub­pro­jects 2 & 3 focus on nov­el treat­ment strate­gies such as immunother­a­py, IncR­NA-based approach­es, and the detec­tion of dereg­u­lat­ed path­ways for mol­e­c­u­lar­ly tar­get­ed therapies.